Insulet (PODD) Revenue & Revenue Breakdown
Insulet Revenue Highlights
Latest Revenue (Y)
$1.70B
Latest Revenue (Q)
$488.50M
Main Segment (Y)
Product, Omnipod
Main Geography (Y)
UNITED STATES
Insulet Revenue by Period
Insulet Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.70B | 30.02% |
| 2022-12-31 | $1.31B | 18.79% |
| 2021-12-31 | $1.10B | 21.49% |
| 2020-12-31 | $904.40M | 22.51% |
| 2019-12-31 | $738.20M | 30.93% |
| 2018-12-31 | $563.82M | 21.57% |
| 2017-12-31 | $463.77M | 26.37% |
| 2016-12-31 | $366.99M | 39.07% |
| 2015-12-31 | $263.89M | -8.60% |
| 2014-12-31 | $288.72M | 16.85% |
| 2013-12-31 | $247.08M | 16.90% |
| 2012-12-31 | $211.37M | 38.83% |
| 2011-12-31 | $152.25M | 57.02% |
| 2010-12-31 | $96.97M | 46.85% |
| 2009-12-31 | $66.03M | 83.12% |
| 2008-12-31 | $36.06M | 169.66% |
| 2007-12-31 | $13.37M | 265.06% |
| 2006-12-31 | $3.66M | 7226.00% |
| 2005-12-31 | $50.00K | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | - |
Insulet generated $1.70B in revenue during NA 2023, up 30.02% compared to the previous quarter, and up 301.00% compared to the same period a year ago.
Insulet Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $488.50M | 10.60% |
| 2024-03-31 | $441.70M | -13.36% |
| 2023-12-31 | $509.80M | 17.82% |
| 2023-09-30 | $432.70M | 9.13% |
| 2023-06-30 | $396.50M | 10.72% |
| 2023-03-31 | $358.10M | -3.14% |
| 2022-12-31 | $369.70M | 8.48% |
| 2022-09-30 | $340.80M | 13.83% |
| 2022-06-30 | $299.40M | 1.35% |
| 2022-03-31 | $295.40M | -4.00% |
| 2021-12-31 | $307.70M | 11.65% |
| 2021-09-30 | $275.60M | 4.71% |
| 2021-06-30 | $263.20M | 4.32% |
| 2021-03-31 | $252.30M | 2.52% |
| 2020-12-31 | $246.10M | 5.17% |
| 2020-09-30 | $234.00M | 3.40% |
| 2020-06-30 | $226.30M | 14.29% |
| 2020-03-31 | $198.00M | -5.44% |
| 2019-12-31 | $209.40M | 9.00% |
| 2019-09-30 | $192.12M | 8.46% |
| 2019-06-30 | $177.14M | 11.02% |
| 2019-03-31 | $159.56M | -3.25% |
| 2018-12-31 | $164.91M | 9.15% |
| 2018-09-30 | $151.08M | 21.58% |
| 2018-06-30 | $124.26M | 0.55% |
| 2018-03-31 | $123.58M | -5.32% |
| 2017-12-31 | $130.52M | 7.18% |
| 2017-09-30 | $121.78M | 10.95% |
| 2017-06-30 | $109.76M | 7.91% |
| 2017-03-31 | $101.71M | -1.80% |
| 2016-12-31 | $103.58M | 9.17% |
| 2016-09-30 | $94.87M | 8.64% |
| 2016-06-30 | $87.33M | 7.53% |
| 2016-03-31 | $81.21M | -18.88% |
| 2015-12-31 | $100.12M | 14.68% |
| 2015-09-30 | $87.30M | 15.50% |
| 2015-06-30 | $75.59M | 23.48% |
| 2015-03-31 | $61.22M | -15.64% |
| 2014-12-31 | $72.56M | -3.23% |
| 2014-09-30 | $74.98M | 4.13% |
| 2014-06-30 | $72.01M | 4.12% |
| 2014-03-31 | $69.16M | 0.92% |
| 2013-12-31 | $68.53M | 12.16% |
| 2013-09-30 | $61.10M | 1.68% |
| 2013-06-30 | $60.09M | 4.77% |
| 2013-03-31 | $57.36M | -0.82% |
| 2012-12-31 | $57.83M | 5.62% |
| 2012-09-30 | $54.75M | 7.28% |
| 2012-06-30 | $51.03M | 6.87% |
| 2012-03-31 | $47.75M | 1.19% |
| 2011-12-31 | $47.19M | 5.83% |
| 2011-09-30 | $44.59M | 38.44% |
| 2011-06-30 | $32.21M | 13.99% |
| 2011-03-31 | $28.26M | 1.77% |
| 2010-12-31 | $27.77M | 9.08% |
| 2010-09-30 | $25.45M | 10.98% |
| 2010-06-30 | $22.94M | 10.24% |
| 2010-03-31 | $20.81M | 2.95% |
| 2009-12-31 | $20.21M | 7.88% |
| 2009-09-30 | $18.73M | 28.17% |
| 2009-06-30 | $14.62M | 17.23% |
| 2009-03-31 | $12.47M | 5.13% |
| 2008-12-31 | $11.86M | 17.32% |
| 2008-09-30 | $10.11M | 36.31% |
| 2008-06-30 | $7.42M | 11.18% |
| 2008-03-31 | $6.67M | 52.97% |
| 2007-12-31 | $4.36M | - |
Insulet generated $488.50M in revenue during Q2 2024, up 10.60% compared to the previous quarter, and up 136.41% compared to the same period a year ago.
Insulet Revenue Breakdown
Insulet Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product, Omnipod | $1.66B | $1.25B | $1.01B | $834.90M | $673.50M |
| International Omnipod | $410.10M | $363.00M | $359.90M | $308.00M | $253.10M |
| Drug Delivery | $36.00M | $57.50M | $87.40M | $69.50M | $64.70M |
| U.S. Omnipod | $1.25B | $884.80M | $651.50M | $526.90M | $420.40M |
Insulet's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product, Omnipod (49.46%), U.S. Omnipod (37.25%), International Omnipod (12.21%), and Drug Delivery (1.07%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Omnipod | $317.70M | $394.60M | $320.60M | $276.80M | $259.00M | $276.20M | $238.10M | $196.40M | $174.10M | $190.50M | $167.20M | $150.50M | $143.30M | $149.20M | $132.30M | $128.80M | $116.60M | $126.76M | $109.46M | $98.07M |
| Drug Delivery | $8.70M | $8.80M | $10.70M | $16.00M | $500.00K | $3.30M | $14.70M | $13.60M | $25.90M | $31.90M | $15.30M | $21.10M | $19.10M | $15.00M | $21.90M | $24.30M | $8.30M | $16.91M | $14.90M | $16.33M |
| International Omnipod | $433.00M | $106.40M | $101.40M | $103.70M | $98.60M | $90.20M | $88.00M | $89.40M | $95.40M | $85.30M | $93.10M | $91.60M | $89.90M | $81.90M | $79.80M | $73.20M | $73.10M | $65.72M | $67.75M | $62.74M |
| Product, Omnipod | $433.00M | $501.00M | $422.00M | $380.50M | $357.60M | $366.40M | $326.10M | $285.80M | $269.50M | $275.80M | $260.30M | $242.10M | $233.20M | $231.10M | $212.10M | $202.00M | $189.70M | - | - | - |
| Product, Diabetes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $177.22M | $160.81M |
Insulet's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: International Omnipod (36.31%), Product, Omnipod (36.31%), U.S. Omnipod (26.64%), and Drug Delivery (0.73%).
Insulet Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-US | $410.10M | $363.00M | $359.90M | $308.00M | $253.10M |
| UNITED STATES | $1.29B | $942.30M | $738.90M | $596.40M | $485.10M |
Insulet's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (75.84%), and Non-US (24.16%).
Insulet Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ABT | Abbott Laboratories | $40.11B | $10.63B |
| SYK | Stryker | $20.50B | $5.49B |
| EW | Edwards Lifesciences | $6.00B | $1.39B |
| ALGN | Align | $3.86B | $1.03B |
| DXCM | DexCom | $3.62B | $994.20M |
| MASI | Masimo | $2.05B | $492.80M |
| PODD | Insulet | $1.70B | $488.50M |
| IART | Integra LifeSciences | $1.54B | $418.18M |
| PEN | Penumbra | $1.06B | $301.04M |
| TNDM | Tandem Diabetes Care | $747.72M | $331.03M |
| SWAV | ShockWave Medical | $730.23M | $218.81M |
| INSP | Inspire Medical Systems | $624.80M | $195.88M |
| NARI | Inari Medical | $493.63M | $153.39M |
| INMD | InMode | $492.05M | $80.28M |
| GKOS | Glaukos | $314.71M | $95.69M |
| TMDX | TransMedics Group | $241.62M | $-12.24M |
PODD Revenue FAQ
What is Insulet’s yearly revenue?
Insulet's yearly revenue for 2023 was $1.7B, representing an increase of 30.02% compared to 2022. The company's yearly revenue for 2022 was $1.31B, representing an increase of 18.79% compared to 2021. PODD's yearly revenue for 2021 was $1.1B, representing an increase of 21.49% compared to 2020.
What is Insulet’s quarterly revenue?
Insulet's quarterly revenue for Q2 2024 was $488.5M, a 10.60% increase from the previous quarter (Q1 2024), and a 23.20% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $441.7M, a -13.36% decrease from the previous quarter (Q4 2023), and a 23.35% increase year-over-year (Q1 2023). PODD's quarterly revenue for Q4 2023 was $509.8M, a 17.82% increase from the previous quarter (Q3 2023), and a 37.90% increase year-over-year (Q4 2022).
What is Insulet’s revenue growth rate?
Insulet's revenue growth rate for the last 3 years (2021-2023) was 54.45%, and for the last 5 years (2019-2023) was 129.90%.
What are Insulet’s revenue streams?
Insulet's revenue streams in c 23 are Product, Omnipod, International Omnipod, Drug Delivery, and U.S. Omnipod. Product, Omnipod generated $1.66B in revenue, accounting 49.46% of the company's total revenue, up 33.12% year-over-year. International Omnipod generated $410.1M in revenue, accounting 12.21% of the company's total revenue, up 12.98% year-over-year. Drug Delivery generated $36M in revenue, accounting 1.07% of the company's total revenue, down -37.39% year-over-year. U.S. Omnipod generated $1.25B in revenue, accounting 37.25% of the company's total revenue, up 41.39% year-over-year.
What is Insulet’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Insulet was Product, Omnipod. This segment made a revenue of $1.66B, representing 49.46% of the company's total revenue.